Diabetes in intraductal papillary mucinous neoplasm of the pancreas and its association with malignancy

J Surg Oncol. 2023 Mar;127(4):625-632. doi: 10.1002/jso.27142. Epub 2022 Nov 21.

Abstract

Background: Intraductal papillary mucinous neoplasms (IPMNs) have the potential to become malignant. Few studies have focused on the prevalence of the diabetes mellitus (DM) in IPMNs and its association with malignancy. We evaluated the association between DM and malignant IPMNs in this study.

Methods: A total of 226 patients with pathologically confirmed IPMNs were included. Demographic data, serum biochemical data, and imaging findings were collected. The malignant IPMNs were defined as those with high-grade dysplasia and associated invasive carcinoma. The association between DM and malignant IPMNs was studied using logistic regression analysis.

Results: The prevalence of DM was 17.7% for all type IPMNs and 31.7% for malignant IPMNs. Compared to patients without DM, those with DM had a 3.6-fold (odds ratio [OR]: 3.62; 95% confidence interval [CI]: 1.26-10.44) higher risk of invasive carcinoma and 2.5-fold (OR: 2.48; 95% CI: 1.06-5.77) higher risk of malignant IPMNs. Similar results were observed in main pancreatic duct (MPD) involved IPMNs. New-onset DM was associated with a 4.13-fold (OR: 4.13, 95% CI: 1.27-13.36) higher risk of invasive carcinoma.

Conclusion: DM is associated with a higher risk of malignant IPMNs and invasive carcinoma, especially in patients with MPD-involved IPMNs.

Keywords: diabetes mellitus; dysplasia; intraductal papillary mucinous neoplasms; invasive carcinoma; pancreas.

MeSH terms

  • Carcinoma, Pancreatic Ductal* / pathology
  • Diabetes Mellitus* / epidemiology
  • Humans
  • Pancreatic Ducts
  • Pancreatic Intraductal Neoplasms* / pathology
  • Pancreatic Neoplasms* / pathology
  • Retrospective Studies